Drug development and evaluation for helminths and other neglected tropical diseasesHelminthiases and other neglected tropical diseases place an enormous burden on developing countries. Yet few drugs are available for control, mechanisms of drug action are poorly understood, and treatment regimens may not be optimal. Moreover, extended drug use risks the development of drug resistance. Thus it is essential to develop new drugs and evaluate how to use current drugs to best effect. This research activity therefore aims to progress candidate drugs into development; generate evidence on efficacy and safety; and determine field safety and effectiveness of registered drugs and optimize their use. Latest news
11 March 2010 Rectal artesunate study wins BMJ research paper of year award
10 March 2010 New WHO malaria treatment guidelines stress need for diagnosis
21 July 2009 Elimination of river blindness feasible: WHO study shows that areas in Mali and Senegal require no further mass treatment
1 July 2009 New drug for river blindness begins Phase 3 clinical trialMoxidectin could dramatically speed up elimination of disease across Africa
2 October 2008 Experts propose simplified system of dengue classification
Why is TDR doing this?TDR has a 25-year track record in drug development and evaluation. It has:
|
2008 Annual Report
The report covers strategic objectives, stakeholders’ roles and key synergies with other activities in TDR and externally. |
Research
Empowerment
Stewardship
Grants
Publications
& resources
Partnerships
& Networks
News &
events
About us
